Mayo Clinic Partners With SV Bio for Clinical Genome Interpretation

Mayo Clinic Partners with SV Bio for Clinical Genomic Interpretation

Mayo Clinic Partners with SV Bio for Clinical Genomic Interpretation

Mayo Clinic announced that Mayo Clinic Center for Individualized Medicine will be collaborating with Silicon Valley Biosciences (SV Bio) for clinical genome interpretation. In the partnership,  SV Bio will offer its clinical genome interpretation services to Mayo Clinic using Mayo Clinics’ laboratory expertise and support.

SV Bio is a diagnostic company based at Foster City CA and it was founded by personal genetics leader  Dietrich A. Stephan, Ph.D.  Dr. Stephen also founded Navigenics in 2006 and helped starting Translational Genomics Research Institute (TGen), Phoenix, AZ. Just last year, Life Technologies acquired Navigenics.

SV Bio has technology that can turn clinical next-gen sequencing data of  a patient’s genome into a meaningful report that can be easily actionable by physicians.

SV Bio claims in its website that its automatic interpretation engine goes beyond standard variant finding and its prediction algorithms can determine the severity of each mutation.  SV Bio’s technology does this knowledge distillation from sequence data to physician actionable report in just a few minutes instead of few days/weeks.

In addition to genomic interpretations, SV Bio has also been offering CLIA certified genome sequencing services and has offered its service to over 300,000 patient samples per year.

In the press release announcing the partnership news with Mayo Clinic, Dr. Stephan said

We are now able to take data from any next-generation sequencer and determine with clinical grade sensitivity and specificity which variants within a patient’s DNA sequence are influencing a disease  or condition, and rapidly provide a report for the clinician that is clear and actionable. This level of speed, accuracy and integration into the clinical work flow is not only a first for molecular  testing, but also a sea change in the application of next-generation sequencing with no compromise of  quality in clinical diagnostics.

Gianrico Farrugia, M.D., director of the Mayo Clinic Center for Individualized Medicine said

At Mayo Clinic, we are committed to integrating genomic medicine into the continuum of care for  all of our patients. The Individualized Medicine Clinic represents one of Mayo’s bold steps toward realizing the  promise of these game-changing technologies and toward offering new hope to patients, including those  with cancer and diagnostic dilemmas.

Speak Your Mind